Annexon, Inc. (ANNX) CMO sells shares to cover tax obligations

Rhea-AI Filing Summary

Annexon, Inc.’s chief medical officer, Jamie Dananberg, reported an open-market sale of 5,820 shares of common stock. The shares were sold to cover tax withholding obligations related to vesting restricted stock units. After this tax-related sale, Dananberg still holds 123,582 Annexon common shares directly.

Insider Trade Summary

Net Seller: 5,820 shares ($31,603)

Net Sell 1 txn

Insider Dananberg Jamie

Role CHIEF MEDICAL OFFICER

Sold 5,820 shs ($32K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,820	$5.43	$32K

Holdings After Transaction: Common Stock — 123,582 shares (Direct)

Footnotes (1)

1. The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). This transaction was executed in multiple trades in prices ranging from $5.36 to $5.57, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dananberg Jamie

(Last) (First) (Middle)

C/O ANNEXON, INC.

1400 SIERRA POINT PKWY, BLDG C, STE 200

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Annexon, Inc. [ ANNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		S(1)		5,820	D	$5.43(2)	123,582	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").

2. This transaction was executed in multiple trades in prices ranging from $5.36 to $5.57, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

	/s/ Jennifer Lew, Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Annexon (ANNX) disclose in this Form 4 filing?

Annexon disclosed that its chief medical officer, Jamie Dananberg, sold 5,820 shares of common stock. The sale was made to cover tax withholding obligations arising from vesting restricted stock units, and Dananberg continues to hold 123,582 Annexon shares directly after the transaction.

How many Annexon (ANNX) shares did the CMO sell and at what price?

Jamie Dananberg sold 5,820 Annexon common shares at a weighted average price of $5.43 per share. The transaction was executed in multiple trades within a price range of $5.36 to $5.57, as detailed in the accompanying Form 4 footnote disclosure.

Why were Jamie Dananberg’s Annexon (ANNX) shares sold in this transaction?

The shares were sold to satisfy tax withholding obligations connected to the vesting of restricted stock units. This means the sale was driven by tax requirements associated with equity compensation, rather than a discretionary decision to reduce overall investment in Annexon stock.

How many Annexon (ANNX) shares does the CMO hold after this Form 4 sale?

After the tax-related sale of 5,820 shares, Jamie Dananberg directly owns 123,582 shares of Annexon common stock. This post-transaction holding amount is reported in the Form 4 as the total number of shares beneficially owned following completion of the sale.

Was the Annexon (ANNX) Form 4 sale an open-market transaction?

Yes. The Form 4 describes the transaction code as an open-market sale, executed across multiple trades between $5.36 and $5.57 per share. However, the stated purpose of the sale was to cover tax withholding on vesting restricted stock units, not a discretionary portfolio adjustment.